• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/20

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

20 Cards in this Set

  • Front
  • Back
Celebrex indication w/ CRC
FDA approved to decrease number of polyps in pts w/ FAP (familial adenomatosis polyposis)
ACS screening guidelines:

average risk
starting age is 50.
colonoscopy q 10 yrs or
sigmoidoscopy, barium enema q5 yrs
ACS screening guidelines:

family history
age 35-40
ACS screening guidelines:

HNPCC (hereditary nonpolyposis colon cancer)
age 30
ACS screening guidelines:

FAP
age 12
CRC 1st stage outside colon
stage III- lymph node involvement
treatment- stage I & II
surgery alone, surveillance, adjuvant chemo????
treatment- stage III
surgery + adjuvant chemo
5-FU based chemo standard
6 mo chemo superior to surgery alone
irinotecan in adjuvant treatment of CRC
no use in adjuvant treatment
Kras that cetuximab responds to
wild-type (non-mutant) Kras
continue bevacizumab after progression?
Yes- improves OS compared to no treatment or other treatment without bevacizumab
tumor marker for CRC
CEA - carcinoembryonic antigen
how to take capecitabine
with meals
DLT for capecitabine
hand/foot syndrome & diarrhea
catabolism of 5FU is by
DPD- dihydropyrimidine dehydrogenase

deficiency= increase tox
bevacizumab CRC dose
5mg/kg q 14 d
enzyme responsible for breakdown of irinotecan
UGT1A1
active metabolite of irinotecan
SN-38
early diarrhea w/ irinotecan treatment is a cholinergic response treated with
atropine 0.25-1mg IV
panitumumab dose
6mg/kg q14d